New standout Imbruvica data bode well for market expansion in CLL

Carly Helfand

Johnson & Johnson and AbbVie's has already shown in one Phase III study that it can extend progression-free survival in patients with previously treated chronic lymphocytic leukemia. But now, it's done it again–and convincingly so.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS